Bristol-Myers Squibb Co. (BMY)

44.05
NYSE : Health Technology
Prev Close 44.13
Day Low/High 43.53 / 44.20
52 Wk Low/High 43.81 / 63.69
Avg Volume 13.09M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 72.18B
EPS 3.00
P/E Ratio 14.05
Div & Yield 1.64 (3.64%)
Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Bristol-Myers Squibb To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Giovanni Caforio, M.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report

3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report

Bristol-Myers, Apple and the economy are some of the top stories on TheStreet.

Dow Drops More Than 600 Points on Apple Warning, China Fears

Dow Drops More Than 600 Points on Apple Warning, China Fears

All three major indices dropped more than 2% Thursday.

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb agrees to buy Celgene in a deal that values the cancer drug specialist at $74 billion.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Video: Jim's Daily Rundown for Thursday

Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Is Bristol-Myers Paying Too Much for Celgene?

Is Bristol-Myers Paying Too Much for Celgene?

BMY agreed to acquire CELG for $74 billion in cash and stock.

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer: Bristol-Myers, Apple, and the Markets

Jim Cramer's back and ready to tackle the Bristol-Myers Celgene deal, Apple and the markets.

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb To Acquire Celgene To Create A Premier Innovative Biopharma Company

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity...

Bristol-Myers Squibb Provides 2019 EPS Guidance

Bristol-Myers Squibb Provides 2019 EPS Guidance

Bristol-Myers Squibb (NYSE:BMY) today announced EPS guidance for full-year 2019.

Bristol-Myers Squibb Announces Offer From Taisho Pharmaceutical Holdings Co., Ltd To Purchase UPSA

Bristol-Myers Squibb Announces Offer From Taisho Pharmaceutical Holdings Co., Ltd To Purchase UPSA

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Taisho Pharmaceutical Holdings Co.

Bristol-Myers Squibb And Boston Medical Center Announce Research Collaboration To Investigate Markers Of Immuno-Oncology Response And Resistance

Bristol-Myers Squibb And Boston Medical Center Announce Research Collaboration To Investigate Markers Of Immuno-Oncology Response And Resistance

Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients...

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) For Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) For Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy, to...

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Bristol-Myers Squibb And Vedanta Biosciences Announce A New Clinical Collaboration To Evaluate OPDIVO (Nivolumab) And VE800 In Patients With Advanced Or Metastatic Cancers

Bristol-Myers Squibb And Vedanta Biosciences Announce A New Clinical Collaboration To Evaluate OPDIVO (Nivolumab) And VE800 In Patients With Advanced Or Metastatic Cancers

Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences' VE800,...

Bristol-Myers Squibb Announces Dividend Increase

Bristol-Myers Squibb Announces Dividend Increase

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019.

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb Company (NYSE: BMY) today announced it will transfer $3.8 billion of U.

TheStreet Quant Rating: C+ (Hold)